Allergan | Jotup

Dr. Chi Li Joins Curevo Vaccine as Chief Regulatory Officer

Retrieved on:

Monday, April 8, 2024

Shingles, Editas Medicine, Regulatory affairs, Bristol Myers Squibb, Doctor of Philosophy, MBA, Rutgers University, Immunization, Johnson & Johnson, Allergan, RAC, Vaccine, Purdue University, Pharmaceutical industry

SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus vaccines with improved tolerability and accessibility, today announced Dr. Chi Li is joining as the company’s Chief Regulatory Officer responsible for the global regulatory strategy for amezosvatein.

Key Points:

SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus vaccines with improved tolerability and accessibility, today announced Dr. Chi Li is joining as the company’s Chief Regulatory Officer responsible for the global regulatory strategy for amezosvatein.
“We are thrilled to have Dr. Li join the Curevo team and build upon the regulatory progress made thus far,” stated George Simeon, Curevo’s Chief Executive Officer.” Dr. Li will play a key role in finalizing our global regulatory strategy and harmonizing our approach to key entry markets in Europe, the USA, China, Japan, and other important markets for our shingles and varicella vaccine.”
Dr. Li’s impressive 20+ year career in regulatory affairs features multiple regulatory successes globally.
“I’m genuinely impressed at what the Curevo team has accomplished to date and am excited to join such a dynamic group,” said Dr. Li.
Previously, Dr. Li served as Vice President, Regulatory Affairs at both Allergan and Bayer.

Sig Kirk Joins Assertio Board of Directors

Retrieved on:

Wednesday, April 3, 2024

AbbVie, Financial management, Certification, Barr Pharmaceuticals, Audit, Business administration, Patient, Pace University, ASRT, Compensation, Allergan, CPA

LAKE FOREST, Ill., April 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced effectiveness of the appointment of Sigurd (Sig) Kirk to its board of directors.

Key Points:

LAKE FOREST, Ill., April 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced effectiveness of the appointment of Sigurd (Sig) Kirk to its board of directors.
Kirk is a senior corporate business development executive with more than 20 years of pharmaceutical experience in the areas of branded biopharmaceutical, medical device and generic products.
Mr. Kirk started his career at Deloitte & Touche as an Audit Manager, earning his CPA certification.
“Both Sig’s appointment and the addition of Sravan Emany last fall demonstrate our ongoing commitment to aligning our board expertise with our evolving business strategies.”

Spectral AI Appoints Jeremiah Sparks as Chief Commercialization Officer

Retrieved on:

Monday, April 1, 2024

Burn, Brigham Young University, Avita Medical, MDAI, Business administration, Patient, Global strategy, Artificial intelligence, Spectral, Publication, Master of Business Administration, Health Economics, Johnson & Johnson, Allergan, Government, Physician, Medtech

DALLAS, April 01, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Jeremiah A. Sparks as Chief Commercialization Officer.

Key Points:

DALLAS, April 01, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Jeremiah A. Sparks as Chief Commercialization Officer.
Jeremiah has more than 20 years of medical device marketing experience, including global marketing and business strategy.
Mr. Sparks will be responsible for both domestic and international product commercialization.
“We are thrilled to have Jeremiah join the company as we move towards commercialization of DeepView,” said Peter M. Carlson, CEO of Spectral AI.

Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler

Retrieved on:

Thursday, March 21, 2024

Glaucoma, B&L, Inflammation, Common, Telecanthus, NIH, CHRO, ISTA, Allergan, Pain, Therapy, Poultry farming

FREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it has formally launched its eye pain treatment program with the hiring of Dr. Simon Chandler.

Key Points:

FREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it has formally launched its eye pain treatment program with the hiring of Dr. Simon Chandler.
The Company believes its sodium channel, NaV1.7 program will be suitable for an array of eye pain indications.
Common acute eye pain indications include corneal foreign body damage or abrasion, acute angle closure glaucoma and post-surgical sequelae.
“The launch of our eye pain treatment program represents a significant milestone for the Company.

3Daughters Announces Three New Appointments to Board of Directors

Retrieved on:

Wednesday, March 13, 2024

Miles, Ph.D., and Sarah J. Stevens, Ph.D., to serve on the Company’s Board of Directors.

Key Points:

Miles, Ph.D., and Sarah J. Stevens, Ph.D., to serve on the Company’s Board of Directors.
An IND for 3D-001 will be filed this year followed by a Phase 1 clinical trial.
Mary Beth Cicero, CEO of 3Daughters, expressed her enthusiasm about the new additions to the board: "We are incredibly excited to have the collective strengths of Michele, Sarah, and Vin on our Board of Directors.
With this first product, 3Daughters expects to disrupt the IUD market and establish a position as a major innovator in women's healthcare.

Deerfield Agency Welcomes Bill Veltre as EVP, Head of Media

Retrieved on:

Wednesday, March 20, 2024

Elsevier, Patient, Digitas Health, PHM, Bristol Myers Squibb, Migraine, CMI, Allergan, WPP, Marketing, Pharmaceutical industry

CONSHOHOCKEN, Pa., March 20, 2024 /PRNewswire/ -- Deerfield Agency, one of the leading health marketing and communications firms for health companies, today announced Bill Veltre has joined as Executive Vice President, Head of Media.

Key Points:

CONSHOHOCKEN, Pa., March 20, 2024 /PRNewswire/ -- Deerfield Agency, one of the leading health marketing and communications firms for health companies, today announced Bill Veltre has joined as Executive Vice President, Head of Media.
With nearly two decades of experience in healthcare marketing, Bill will direct paid media services for the agency, guiding further development of the company's strategic and analytical approach to media and digital strategy.
"Bill's appointment signifies an exciting milestone for Deerfield Agency as our media service offerings grow and we continue to enhance our media insights and reporting capabilities," said Frank Burrell, Managing Partner at Deerfield.
Bill is a seasoned healthcare marketing professional with expertise in the successful integration of media, creative, and analytics.

Syndax Announces Appointment of Steven Closter as Chief Commercial Officer

Retrieved on:

Monday, March 18, 2024

Psychiatry, Growth, Neurology, Sunovion, Business administration, Cornell University, Patient, CNS, SNDX, Cancer, Marketing, Forest Laboratories, Allergan, Therapy, Pharmaceutical industry

WALTHAM, Mass., March 18, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Steven Closter as Chief Commercial Officer, effective immediately. Mr. Closter will lead the Company's commercial strategy and operations, including marketing, sales, and market access, succeeding Steve Sabus, who is departing for personal reasons.

Key Points:

WALTHAM, Mass., March 18, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the appointment of Steven Closter as Chief Commercial Officer, effective immediately.
"Steven Closter is an accomplished leader with a proven track record of building commercial teams, leading successful product launches and delivering growth across a broad range of therapeutic areas," said Michael A. Metzger, Chief Executive Officer.
Mr. Closter brings to Syndax over 30 years of commercial experience, which included the oversight of over a dozen product launches and indication expansions.
Mr. Metzger added: "We thank Steve Sabus for his contributions to Syndax and for his assistance in seamlessly transitioning the role to Steven Closter.

Assertio Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on:

Monday, March 11, 2024

Acquisition, Barr Pharmaceuticals, Growth, AbbVie, Eye, Allergan, Mason, Trial of the century, Video game

LAKE FOREST, Il., March 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points:

Rolvedon net product sales were $11.0 million in the fourth quarter, the first full quarter following the acquisition of Spectrum.
Gross margin3 in the fourth quarter was 70%, decreased from 88% in the prior year fourth quarter.
Assertio announced its initial 2024 operating guidance as follows:
For the quarter ended December 31, 2023, cash and cash equivalents totaled $73.4 million.
Assertio’s management will host a conference call to discuss its fourth quarter and full year 2023 financial results today:

Veza Appoints Mike Towers as Chief Security & Trust Officer

Retrieved on:

Wednesday, March 6, 2024

Veza , the Identity Security company, today announced the appointment of Mike Towers as Chief Security & Trust Officer.

Key Points:

Veza , the Identity Security company, today announced the appointment of Mike Towers as Chief Security & Trust Officer.
View the full release here: https://www.businesswire.com/news/home/20240306718981/en/
As a career security executive and recognized expert in digital transformation and trust, Towers’ arrival marks a significant addition to Veza’s senior leadership team.
His previous tenure as Chief Digital Trust Officer at Takeda, coupled with his time as Chief Information Security Officer (CISO) at Allergan plc and GlaxoSmithKline (GSK), has equipped Towers with the hands-on experience to advance trusted digital and data platforms, and ultimately transform how leading organizations secure and manage access in today’s interconnected world.
“With Veza, we are taking on cybersecurity’s toughest challenge - helping organizations understand who can take what action on what data,” said Tarun Thakur, Co-Founder & CEO, Veza.

Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer

Retrieved on:

Thursday, February 15, 2024

“We are pleased to welcome Katie to Scholar Rock’s Board of Directors at a pivotal time when the company is preparing for the potential launch of apitegromab next year,” said David Hallal, Chairman of the Board of Scholar Rock.

Key Points:

“We are pleased to welcome Katie to Scholar Rock’s Board of Directors at a pivotal time when the company is preparing for the potential launch of apitegromab next year,” said David Hallal, Chairman of the Board of Scholar Rock.
Katie joining our Board reflects the continued evolution of Scholar Rock, and as part of this process, Amir Nashat will be stepping down from the Board at this year’s annual shareholder meeting.
Prior to joining Denali, Ms. Peng managed a neurology, ophthalmology, immunology, and rare disease portfolio representing approximately $14 billion in revenue at Genentech.
“I am thrilled to join Scholar Rock’s Board of Directors as the company prepares for its first potential commercial launch of apitegromab.